{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:02:50Z","timestamp":1790647370780,"version":"4.1.0"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00667-1","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:36:57Z","timestamp":1790645817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting neurovascular dysfunction in diabetic neuropathic pain: a review of mechanism-based pharmacotherapy beyond gabapentinoids"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2993-5348","authenticated-orcid":false,"given":"Abhishek","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0085-4965","authenticated-orcid":false,"given":"Aman","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0067-2787","authenticated-orcid":false,"given":"Paras","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7544-6881","authenticated-orcid":false,"given":"Rakesh","family":"Barik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-5555","authenticated-orcid":false,"given":"Abhishek","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2732-5968","authenticated-orcid":false,"given":"Prerna","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5305-7513","authenticated-orcid":false,"given":"Kuldeep","family":"Upadhayay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-4812","authenticated-orcid":false,"given":"Sumeet","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5819-371X","authenticated-orcid":false,"given":"Jeetendra Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"667_CR1","doi-asserted-by":"publisher","first-page":"116392","DOI":"10.1016\/j.biopha.2024.116392","volume":"173","author":"S-M Hwang","year":"2024","unstructured":"Hwang S-M, Rahman MM, Go EJ, Kim YH, Park C-KJB. Specific transcription factors Ascl1 and Lhx6 attenuate diabetic neuropathic pain by modulating spinal neuroinflammation and microglial activation in mice. Pharmacotherapy. 2024;173:116392.","journal-title":"Pharmacotherapy"},{"key":"667_CR2","doi-asserted-by":"crossref","unstructured":"He J, Qin Z, Chen X, He W, Li D, Zhang L et al. HIF-1\u03b1 Ameliorates Diabetic Neuropathic Pain via Parkin\u2010Mediated Mitophagy in a Mouse Model. 2022;2022(1):5274375.","DOI":"10.1155\/2022\/5274375"},{"key":"667_CR3","doi-asserted-by":"crossref","unstructured":"Sivitz WI, Yorek MAJA, signaling r. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. 2010;12(4):537\u201377.","DOI":"10.1089\/ars.2009.2531"},{"key":"667_CR4","doi-asserted-by":"crossref","unstructured":"Jensen TS, Karlsson P, Gylfadottir SS, Andersen ST, Bennett DL, Tankisi H et al. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. 2021;144(6):1632\u201345.","DOI":"10.1093\/brain\/awab079"},{"key":"667_CR5","doi-asserted-by":"crossref","unstructured":"Doty M, Yun S, Wang Y, Hu M, Cassidy M, Hall B et al. Integrative multiomic analyses of dorsal root ganglia in diabetic neuropathic pain using proteomics, phospho-proteomics, and metabolomics. 2022;12(1):17012.","DOI":"10.1038\/s41598-022-21394-y"},{"key":"667_CR6","first-page":"107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International. Diabetes Federation Diabetes Atlas. 2019;157:107843.","journal-title":"Diabetes Federation Diabetes Atlas"},{"issue":"964","key":"667_CR7","first-page":"95","volume":"82","author":"V Bansal","year":"2006","unstructured":"Bansal V, Kalita J, Misra UJP. Diabet neuropathy. 2006;82(964):95\u2013100.","journal-title":"Diabet neuropathy"},{"issue":"3","key":"667_CR8","first-page":"432","volume":"6","author":"AK Schreiber","year":"2015","unstructured":"Schreiber AK, Nones CF, Reis RC, Chichorro JG. Cunha JMJWjod. Diabet neuropathic pain: physiopathology Treat. 2015;6(3):432.","journal-title":"Diabet neuropathic pain: physiopathology Treat"},{"key":"667_CR9","doi-asserted-by":"crossref","unstructured":"Alam U, Sloan G, Tesfaye SJD. Treating pain in diabetic neuropathy: current and developmental drugs. 2020;80(4):363\u201384.","DOI":"10.1007\/s40265-020-01259-2"},{"key":"667_CR10","doi-asserted-by":"crossref","unstructured":"Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai K-S, Stacey BJJ et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. 2005;30(4):374\u201385.","DOI":"10.1016\/j.jpainsymman.2005.04.009"},{"key":"667_CR11","doi-asserted-by":"crossref","unstructured":"Bhandari R, Sharma A, Kuhad AJFE. Novel nanotechnological approaches for targeting dorsal root ganglion (DRG) in mitigating diabetic neuropathic pain (DNP). 2022;12:790747.","DOI":"10.3389\/fendo.2021.790747"},{"key":"667_CR12","doi-asserted-by":"crossref","unstructured":"Grasso G, Landi A, Alafaci CJMM. A novel pathophysiological mechanism contributing to trigeminal neuralgia. 2016;22(1):452\u20134.","DOI":"10.2119\/molmed.2016.00172"},{"key":"667_CR13","doi-asserted-by":"crossref","unstructured":"Gong N, Park J, Luo ZDJBJP. Injury-induced maladaptation and dysregulation of calcium channel \u03b12\u03b4 subunit proteins and its contribution to neuropathic pain development. 2018;175(12):2231\u201343.","DOI":"10.1111\/bph.13930"},{"key":"667_CR14","unstructured":"Intelligence D. August,. Diabetic Neuropathy Market Size, Share, Growth, Report 2025- DataM Intelligence 2025 [updated 28 2025. Available from:"},{"key":"667_CR15","doi-asserted-by":"crossref","unstructured":"Wild S, Roglic G, Green A, Sicree R, King, HJDc. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. 2004;27(5):1047\u201353.","DOI":"10.2337\/diacare.27.5.1047"},{"key":"667_CR16","unstructured":"Hellebo A. The economic burden, patients\u2019 well-being, and social determinants related to diabetes in South Africa. 2024."},{"key":"667_CR17","doi-asserted-by":"crossref","unstructured":"Rosenberger DC, Blechschmidt V, Timmerman H, Wolff A, Treede R-DJJNT. Challenges of neuropathic pain: focus on diabetic neuropathy. 2020;127(4):589\u2013624.","DOI":"10.1007\/s00702-020-02145-7"},{"key":"667_CR18","doi-asserted-by":"crossref","unstructured":"Elliott J, Sloan G, Stevens L, Selvarajah D, Cruccu G, Gandhi RA et al. Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study. 2024;67(1):190\u20138.","DOI":"10.1007\/s00125-023-06025-z"},{"key":"667_CR19","doi-asserted-by":"crossref","unstructured":"Zhou P, Zhou Js L, Jj, Qin L, Hu Wf Z, Xy et al. Prevalence and risk factors for painful diabetic peripheral neuropathy: a systematic review and meta-analysis. 2025;16:1564867.","DOI":"10.3389\/fneur.2025.1564867"},{"key":"667_CR20","doi-asserted-by":"crossref","unstructured":"Huang C-C, Lee C-L, Huang M-H, Chen T-W, Weng M-C, Tseng H-CJTKJMS. Effect of glycemic control on electrophysiologic changes of diabetic neuropathy in type 2 diabetic patients. 2005;21(1):15\u201321.","DOI":"10.1016\/S1607-551X(09)70271-2"},{"key":"667_CR21","doi-asserted-by":"crossref","unstructured":"Tao Y, Zhang H, MacGilchrist C, Kirwan E. McIntosh CJDr, practice c. Prevalence and risk factors of painful diabetic neuropathy: A systematic review and meta-analysis. 2025:112099.","DOI":"10.1016\/j.diabres.2025.112099"},{"key":"667_CR22","doi-asserted-by":"crossref","unstructured":"Hicks CW, Selvin EJC. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. 2019;19(10):86.","DOI":"10.1007\/s11892-019-1212-8"},{"key":"667_CR23","doi-asserted-by":"crossref","unstructured":"Fischer TZ, Waxman SGJNRN. Neuropathic pain in diabetes\u2014evidence for a central mechanism. 2010;6(8):462\u20136.","DOI":"10.1038\/nrneurol.2010.90"},{"key":"667_CR24","doi-asserted-by":"crossref","unstructured":"Pang L, Lian X, Liu H, Zhang Y, Li Q, Cai Y et al. Understanding diabetic neuropathy: focus on oxidative stress. 2020;2020(1):9524635.","DOI":"10.1155\/2020\/9524635"},{"key":"667_CR25","doi-asserted-by":"crossref","unstructured":"Li Y, Kong E, Ding R, Chu R, Lu J, Deng M et al. Hyperglycemia-induced Sirt3 downregulation increases microglial aerobic glycolysis and inflammation in diabetic neuropathic pain pathogenesis. 2024;30(8):e14913.","DOI":"10.1111\/cns.14913"},{"key":"667_CR26","doi-asserted-by":"crossref","unstructured":"Feldman EL, Nave K-A, Jensen TS, Bennett DLJN. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. 2017;93(6):1296\u2013313.","DOI":"10.1016\/j.neuron.2017.02.005"},{"key":"667_CR27","doi-asserted-by":"crossref","unstructured":"Chung SS, Ho EC, Lam KS, Chung SKJJASN. Contribution of polyol pathway to diabetes-induced oxidative stress. 2003;14(suppl_3):S233\u20136.","DOI":"10.1097\/01.ASN.0000077408.15865.06"},{"key":"667_CR28","doi-asserted-by":"crossref","unstructured":"Oates PJJCdt. Aldose reductase, still a compelling target for diabetic neuropathy. 2008;9(1):14\u201336.","DOI":"10.2174\/138945008783431781"},{"key":"667_CR29","doi-asserted-by":"crossref","unstructured":"Chen Y, Song X-JJB. Diabetic neuropathic pain: directions for exploring treatments. 2024;12(3):589.","DOI":"10.3390\/biomedicines12030589"},{"key":"667_CR30","first-page":"1265372","volume":"14","author":"J Zhu","year":"2024","unstructured":"Zhu J, Hu Z, Luo Y, Liu Y, Luo W, Du X, et al. Diabet peripheral neuropathy: pathogenetic Mech Treat. 2024;14:1265372.","journal-title":"Diabet peripheral neuropathy: pathogenetic Mech Treat"},{"key":"667_CR31","doi-asserted-by":"crossref","unstructured":"Yang J-X, Wang H-F, Chen J-Z, Li H-Y, Hu J-C, Yu A-A et al. Potential neuroimmune interaction in chronic pain: a review on immune cells in peripheral and central sensitization. 2022;3:946846.","DOI":"10.3389\/fpain.2022.946846"},{"key":"667_CR32","doi-asserted-by":"crossref","unstructured":"Zhao L, Li D, Liu N, Liu L, Zhang Z, Gao C et al. Correlation of TGN-020 with the analgesic effects via ERK pathway activation after chronic constriction injury. 2018;14:1744806918796057.","DOI":"10.1177\/1744806918796057"},{"key":"667_CR33","doi-asserted-by":"crossref","unstructured":"Ye D, Fairchild TJ, Vo L, Drummond PDJDM. Painful diabetic peripheral neuropathy: role of oxidative stress and central sensitisation. 2022;39(1):e14729.","DOI":"10.1111\/dme.14729"},{"issue":"1","key":"667_CR34","first-page":"19","volume":"16","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Wang J, Li H, Xia LJJI. IL-35 alleviates inflammation progression in a rat model of diabetic neuropathic pain via inhibition of. JNK Signal. 2019;16(1):19.","journal-title":"JNK Signal"},{"key":"667_CR35","doi-asserted-by":"crossref","unstructured":"Woolf CJJp. Central sensitization: implications for the diagnosis and treatment of pain. 2011;152(3):S2\u201315.","DOI":"10.1016\/j.pain.2010.09.030"},{"key":"667_CR36","doi-asserted-by":"crossref","unstructured":"Coderre TJ, Katz JJB, Sciences B. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. 1997;20(3):404\u201319.","DOI":"10.1017\/S0140525X97251484"},{"key":"667_CR37","doi-asserted-by":"crossref","unstructured":"Antal MJIJoMS. Molecular anatomy of synaptic and extrasynaptic neurotransmission between nociceptive primary afferents and spinal dorsal horn neurons. 2025;26(5):2356.","DOI":"10.3390\/ijms26052356"},{"key":"667_CR38","doi-asserted-by":"crossref","unstructured":"Shkodra M, Brunelli C, Zecca E, Infante G, Miceli R, Caputo M et al. Cancer pain: Results of a prospective study on prognostic indicators of pain intensity including pain syndromes assessment. 2022;36(9):1396\u2013407.","DOI":"10.1177\/02692163221122354"},{"key":"667_CR39","doi-asserted-by":"crossref","unstructured":"Ma Y-c, Kang Z-b, Shi Y-q, Ji W-y. Zhou W-m, Nan WJJoIN. The complexity of neuropathic pain and central sensitization: exploring mechanisms and therapeutic prospects. 2024;23(5):89.","DOI":"10.31083\/j.jin2305089"},{"key":"667_CR40","doi-asserted-by":"crossref","unstructured":"Zhou J. Zhou SJMn. Inflammation: therapeutic targets for diabetic neuropathy. 2014;49(1):536\u2009\u2013\u200946.","DOI":"10.1007\/s12035-013-8537-0"},{"key":"667_CR41","doi-asserted-by":"crossref","unstructured":"Baum P, Toyka KV, Bl\u00fcher M, Kosacka J, Nowicki MJIJMS. Inflammatory mechanisms in the pathophysiology of diabetic peripheral neuropathy (DN)\u2014new aspects. 2021;22(19):10835.","DOI":"10.3390\/ijms221910835"},{"key":"667_CR42","first-page":"921612","volume":"13","author":"X-X Fang","year":"2022","unstructured":"Fang X-X, Wang H, Song H-L, Wang J, Zhang Z-JJFP. Neuroinflammation involved diabetes-related pain itch. 2022;13:921612.","journal-title":"Neuroinflammation involved diabetes-related pain itch"},{"key":"667_CR43","doi-asserted-by":"crossref","unstructured":"Palumbo L, Carinci M, Guarino A, Asth L, Zucchini S, Missiroli S et al. The NLRP3 inflammasome in neurodegenerative disorders: insights from epileptic models. 2023;11(10):2825.","DOI":"10.3390\/biomedicines11102825"},{"key":"667_CR44","doi-asserted-by":"crossref","unstructured":"Darabniya AJI. The neuroinflammatory triumvirate: NF-\u03baB, NLRP3, and mTOR in spinal cord injury. 2025;33(10):5769\u201375.","DOI":"10.1007\/s10787-025-01952-2"},{"key":"667_CR45","doi-asserted-by":"crossref","unstructured":"Ristikj-Stomnaroska D, Risteska-Nejashmikj V, Papazova MJOM. Role of inflammation in the pathogenesis of diabetic peripheral neuropathy. 2019;7(14):2267.","DOI":"10.3889\/oamjms.2019.646"},{"key":"667_CR46","doi-asserted-by":"crossref","unstructured":"Cheng Y, Chen Y, Li K, Liu S, Pang C, Gao L et al. How inflammation dictates diabetic peripheral neuropathy: An enlightening review. 2024;30(4):e14477.","DOI":"10.1111\/cns.14477"},{"key":"667_CR47","doi-asserted-by":"crossref","unstructured":"Finnerup NB, Kuner R, Jensen TSJP. Neuropathic pain: from mechanisms to treatment. 2021;101(1):259\u2013301.","DOI":"10.1152\/physrev.00045.2019"},{"key":"667_CR48","first-page":"108546","volume":"251","author":"M Thouaye","year":"2023","unstructured":"Thouaye M, Yalcin IJP. Neuropathic pain: From actual pharmacological treatments to new therapeutic horizons. Therapeutics. 2023;251:108546.","journal-title":"Therapeutics"},{"key":"667_CR49","doi-asserted-by":"crossref","unstructured":"Cavalli E, Mammana S, Nicoletti F, Bramanti P. Mazzon EJIjoi, pharmacology. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. 2019;33:2058738419838383.","DOI":"10.1177\/2058738419838383"},{"key":"667_CR50","doi-asserted-by":"crossref","unstructured":"Harden N. Cohen MJJop, management s. Unmet needs in the management of neuropathic pain. 2003;25(5):S12-S7.","DOI":"10.1016\/S0885-3924(03)00065-4"},{"issue":"11","key":"667_CR51","first-page":"3002","volume":"11","author":"P Shinu","year":"2022","unstructured":"Shinu P, Morsy MA, Nair AB, Mouslem AKA, Venugopala KN, Goyal M, et al. Novel Ther Treat neuropathic pain: potential pitfalls. 2022;11(11):3002.","journal-title":"Novel Ther Treat neuropathic pain: potential pitfalls"},{"key":"667_CR52","doi-asserted-by":"crossref","unstructured":"Wake H, Moorhouse AJ, Nabekura JJN. Functions of microglia in the central nervous system\u2013beyond the immune response. 2011;7(1):47\u201353.","DOI":"10.1017\/S1740925X12000063"},{"key":"667_CR53","doi-asserted-by":"crossref","unstructured":"Vanderwall AG, Milligan, EDJFii. Cytokines in pain: harnessing endogenous anti-inflammatory signaling for improved pain management. 2019;10:3009.","DOI":"10.3389\/fimmu.2019.03009"},{"key":"667_CR54","first-page":"1648887","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Fang C, Li Y, Xiong X, Xu X, Gu LJFI. Glycolytic reprogramming Dur microglial polarization Neurol Dis. 2025;16:1648887.","journal-title":"Glycolytic reprogramming Dur microglial polarization Neurol Dis"},{"issue":"3","key":"667_CR55","first-page":"227","volume":"94","author":"MJ Snyder","year":"2016","unstructured":"Snyder MJ, Gibbs LM, Lindsay TJJA. Treat painful Diabet peripheral neuropathy: update. 2016;94(3):227\u201334.","journal-title":"Treat painful Diabet peripheral neuropathy: update"},{"key":"667_CR56","doi-asserted-by":"crossref","unstructured":"Rowbotham MC, Goli V, Kunz NR, Lei DJP. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. 2004;110(3):697\u2013706.","DOI":"10.1016\/j.pain.2004.05.010"},{"key":"667_CR57","doi-asserted-by":"crossref","unstructured":"Chen K-Y, Li R-YJP. Efficacy and safety of different antidepressants and anticonvulsants in central poststroke pain: A network meta-analysis and systematic review. 2022;17(10):e0276012.","DOI":"10.1371\/journal.pone.0276012"},{"key":"667_CR58","doi-asserted-by":"crossref","unstructured":"Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. 1998;280(21):1831\u20136.","DOI":"10.1001\/jama.280.21.1831"},{"key":"667_CR59","doi-asserted-by":"crossref","unstructured":"Majdinasab N, Kaveyani H. Azizi MJDd, development, therapy. A comparative double-blind randomized study on the effectiveness of duloxetine and gabapentin on painful diabetic peripheral polyneuropathy. 2019:1985\u201392.","DOI":"10.2147\/DDDT.S185995"},{"key":"667_CR60","volume-title":"editor Gabapentin relieves abnormal pain in a rat model of painful peripheral neuropathy","year":"1995","unstructured":"WM X. editor Gabapentin relieves abnormal pain in a rat model of painful peripheral neuropathy. Soc Neurosci Abstr; 1995."},{"key":"667_CR61","doi-asserted-by":"crossref","unstructured":"Bennett GJ, Xie Y-KJP. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. 1988;33(1):87\u2013107.","DOI":"10.1016\/0304-3959(88)90209-6"},{"key":"667_CR62","doi-asserted-by":"crossref","unstructured":"Chong MS, Hester JJD. Diabetic painful neuropathy: current and future treatment options. 2007;67(4):569\u201385.","DOI":"10.2165\/00003495-200767040-00006"},{"key":"667_CR63","doi-asserted-by":"crossref","unstructured":"Pan Y, Davis PB, Kaebler DC, Blankfield RP, Xu RJCD. Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy. 2022;21(1):170.","DOI":"10.1186\/s12933-022-01610-9"},{"key":"667_CR64","doi-asserted-by":"crossref","unstructured":"Syed O, Jancic P, Knezevic NNJP. A review of recent pharmacological advances in the management of diabetes-associated peripheral neuropathy. 2023;16(6):801.","DOI":"10.3390\/ph16060801"},{"key":"667_CR65","doi-asserted-by":"crossref","unstructured":"Bielewicz J, Kamieniak M, Szymoniuk M, Litak J, Czy\u017cewski W, Kamieniak PJJoCM. Diagnosis and management of neuropathic pain in spine diseases. 2023;12(4):1380.","DOI":"10.3390\/jcm12041380"},{"key":"667_CR66","volume-title":"Orofacial Pain Operant Analysis with Concomitant Investigation of Peripherally Restricted Cannabinoids and Nav1. 8 Axonal Accumulation for the Potential Treatment of Neuropathic Pain","author":"Y Mulpuri","year":"2015","unstructured":"Mulpuri Y. Orofacial Pain Operant Analysis with Concomitant Investigation of Peripherally Restricted Cannabinoids and Nav1. 8 Axonal Accumulation for the Potential Treatment of Neuropathic Pain. University of California, Los Angeles; 2015."},{"key":"667_CR67","doi-asserted-by":"crossref","unstructured":"Mian MU, Afzal M, Butt AA, Ijaz M, Khalil K, Abbasi M et al. Neuropharmacology of neuropathic pain: a systematic review. 2024;16(9).","DOI":"10.7759\/cureus.69028"},{"issue":"Supplement1","key":"667_CR68","first-page":"S2","volume":"20","author":"D Bates","year":"2019","unstructured":"Bates D, Schultheis BC, Hanes MC, Jolly SM, Chakravarthy KV, Deer TR, et al. Compr algorithm Manage neuropathic pain. 2019;20(Supplement1):S2\u201312.","journal-title":"Compr algorithm Manage neuropathic pain"},{"key":"667_CR69","doi-asserted-by":"crossref","unstructured":"Khdour, MRJJoP. Pharmacology. Treatment of diabetic peripheral neuropathy: a review. 2020;72(7):863\u201372.","DOI":"10.1111\/jphp.13241"},{"key":"667_CR70","doi-asserted-by":"crossref","unstructured":"Huang Y, Chen H, Chen S-R, Pan H-LJA. Duloxetine and amitriptyline reduce neuropathic pain by inhibiting primary sensory input to spinal dorsal horn neurons via \u03b11-and \u03b12-adrenergic receptors. 2023;14(7):1261.","DOI":"10.1021\/acschemneuro.2c00780"},{"issue":"19","key":"667_CR71","first-page":"11418","volume":"23","author":"M De Russo","year":"2022","unstructured":"Russo M, De Rosa MA, Calisi D, Consoli S, Evangelista G, Dono F, et al. Migraine Pharmacol Treat Cogn impairment: risks benefits. 2022;23(19):11418.","journal-title":"Migraine Pharmacol Treat Cogn impairment: risks benefits"},{"issue":"11","key":"667_CR72","first-page":"3779","volume":"120","author":"MH Ossipov","year":"2010","unstructured":"Ossipov MH, Dussor GO, Porreca FJTJ. Cent modulation pain. 2010;120(11):3779\u201387.","journal-title":"Cent modulation pain"},{"key":"667_CR73","doi-asserted-by":"crossref","unstructured":"Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJJDC. control? Does treatment with duloxetine for neuropathic pain impact glycemic 2007;30(1):21\u20136.","DOI":"10.2337\/dc06-0947"},{"key":"667_CR74","doi-asserted-by":"crossref","unstructured":"Freeman R, Raskin P, Hewitt DJ, Vorsanger GJ, Jordan DM, Xiang J et al. Randomized study of tramadol\/acetaminophen versus placebo in painful diabetic peripheral neuropathy. 2007;23(1):147\u201361.","DOI":"10.1185\/030079906X162674"},{"key":"667_CR75","doi-asserted-by":"crossref","unstructured":"Price R, Smith D, Franklin G, Gronseth G, Pignone M, David WS et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN guideline subcommittee. 2022;98(1):31\u201343.","DOI":"10.1212\/WNL.0000000000013038"},{"key":"667_CR76","doi-asserted-by":"crossref","unstructured":"Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. 1998;50(6):1842\u20136.","DOI":"10.1212\/WNL.50.6.1842"},{"key":"667_CR77","first-page":"112717","volume":"148","author":"K Yang","year":"2022","unstructured":"Yang K, Wang Y, Li Y-w, Chen Y-g, Xing N, Lin H-b, et al. Progress Treat Diabet peripheral neuropathy. 2022;148:112717.","journal-title":"Progress Treat Diabet peripheral neuropathy"},{"key":"667_CR78","doi-asserted-by":"crossref","unstructured":"Kushnarev M, Pirvulescu IP, Candido KD, Knezevic NNJE. Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers. 2020;29(3):259\u201371.","DOI":"10.1080\/13543784.2020.1728254"},{"key":"667_CR79","doi-asserted-by":"crossref","unstructured":"Liu M, Wood JNJP. The roles of sodium channels in nociception: implications for mechanisms of neuropathic pain. 2011;12(suppl_3):S93\u20139.","DOI":"10.1111\/j.1526-4637.2011.01158.x"},{"key":"667_CR80","doi-asserted-by":"crossref","unstructured":"McDonnell A, Collins S, Ali Z, Iavarone L, Surujbally R, Kirby S et al. Efficacy of the Nav1. 7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. 2018;159(8):1465\u201376.","DOI":"10.1097\/j.pain.0000000000001227"},{"key":"667_CR81","doi-asserted-by":"crossref","unstructured":"Iwane S, Nemoto W, Miyamoto T, Hayashi T, Tanaka M, Uchitani K et al. Clinical and preclinical evidence that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prevent diabetic peripheral neuropathy. 2024;14(1):1039.","DOI":"10.1038\/s41598-024-51572-z"},{"key":"667_CR82","doi-asserted-by":"crossref","unstructured":"Keppel Hesselink JM, Schatman MEJJPR. EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain. 2017:439\u2009\u2013\u200943.","DOI":"10.2147\/JPR.S128520"},{"key":"667_CR83","doi-asserted-by":"crossref","unstructured":"Rice AS, Dworkin RH, Finnerup NB, Attal N, Anand P, Freeman R et al. Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. 2021;162(10):2578\u201389.","DOI":"10.1097\/j.pain.0000000000002252"},{"key":"667_CR84","doi-asserted-by":"crossref","unstructured":"Smith MT, Muralidharan AJEoott. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. 2015;19(1):25\u201335.","DOI":"10.1517\/14728222.2014.957673"},{"key":"667_CR85","doi-asserted-by":"crossref","unstructured":"Mao JJTips. Current challenges in translational pain research. 2012;33(11):568\u201373.","DOI":"10.1016\/j.tips.2012.08.001"},{"key":"667_CR86","doi-asserted-by":"crossref","unstructured":"Owens BJN. Drug development: The treasure chest. 2015;525(7570):S6\u20138.","DOI":"10.1038\/525S6a"},{"key":"667_CR87","doi-asserted-by":"crossref","unstructured":"Fontelles MIM, Garc\u00eda CGJC. Role of cannabinoids in the management of neuropathic pain. 2008;22(8):645\u201353.","DOI":"10.2165\/00023210-200822080-00003"},{"key":"667_CR88","doi-asserted-by":"crossref","unstructured":"Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JHJTJP. Efficacy of inhaled cannabis on painful diabetic neuropathy. 2015;16(7):616\u201327.","DOI":"10.1016\/j.jpain.2015.03.008"},{"key":"667_CR89","doi-asserted-by":"crossref","unstructured":"M\u00fccke M, Phillips T, Radbruch L, Petzke F, H\u00e4user WJC. Cannabis-based medicines for chronic neuropathic pain in adults. 2018(3).","DOI":"10.1002\/14651858.CD012182.pub2"},{"key":"667_CR90","doi-asserted-by":"crossref","unstructured":"Al-Kaisy A, Van Buyten J-P, Smet I, Palmisani S, Pang D, Smith TJPM. Sustained effectiveness of 10 kHz high-frequency spinal cord stimulation for patients with chronic, low back pain: 24-month results of a prospective multicenter study. 2014;15(3):347\u201354.","DOI":"10.1111\/pme.12294"},{"key":"667_CR91","doi-asserted-by":"crossref","unstructured":"Petersen EA, Sills SM, Stauss TG, Province-Azalde R, Jaasma MJ, Edgar DR et al. Long\u2010term efficacy of 10 kHz spinal cord stimulation in managing painful diabetic neuropathy: A post\u2010study survey. 2025;25(5):e70023.","DOI":"10.1111\/papr.70023"},{"key":"667_CR92","doi-asserted-by":"crossref","unstructured":"Hussain N, Said AS, Javaid FA, Al Haddad AHI, Anwar M, Khan Z et al. The efficacy and safety profile of capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of south Asian male patients. 2021;20(1):271\u20138.","DOI":"10.1007\/s40200-021-00741-2"},{"key":"667_CR93","doi-asserted-by":"crossref","unstructured":"\u00dcberall M, B\u00f6sl I, Hollanders E, Sabatschus I. Eerdekens MJBodr, care. Painful diabetic peripheral neuropathy: real-world comparison between topical treatment with lidocaine 700 mg medicated plaster and oral treatments. 2022;10(6).","DOI":"10.1136\/bmjdrc-2022-003062"},{"key":"667_CR94","doi-asserted-by":"crossref","unstructured":"Sloan G, Alam U, Selvarajah D, Tesfaye SJC. The treatment of painful diabetic neuropathy. 2022;18(5):42\u201396.","DOI":"10.2174\/1573399817666210707112413"},{"key":"667_CR95","doi-asserted-by":"crossref","unstructured":"Lawson E, Singla P, Adler J, Argoff CE, Bettinger JJ, Bhaskar A et al. Topical analgesics for neuropathic pain: an evidence-informed guide for the practicing clinician. 2025:pnaf130.","DOI":"10.1093\/pm\/pnaf130"},{"key":"667_CR96","doi-asserted-by":"crossref","unstructured":"Landrum O, Marcondes L, Egharevba T, Gritsenko KJPM. Painful diabetic peripheral neuropathy of the feet: integrating prescription-strength capsaicin into office procedures. 2023;13(10):613\u201326.","DOI":"10.2217\/pmt-2023-0028"},{"issue":"1","key":"667_CR97","first-page":"121","volume":"29","author":"R Ryan","year":"2025","unstructured":"Ryan R, Judge R, Lou J, Ng AJCP, Reports H. Capsaicin in the Management of Peripheral Neuropathy. Rev. 2025;29(1):121.","journal-title":"Rev"},{"key":"667_CR98","doi-asserted-by":"crossref","unstructured":"Mallick-Searle T, Adler JAJJPR. Update on treating painful Diabetic Peripheral Neuropathy: a review of current US guidelines with a focus on the most recently approved Management options. 2024:1005\u201328.","DOI":"10.2147\/JPR.S442595"},{"key":"667_CR99","doi-asserted-by":"crossref","unstructured":"Simpson DM, Robinson-Papp J, Van J, Stoker M, Jacobs H, Snijder RJ et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. 2017;18(1):42\u201353.","DOI":"10.1016\/j.jpain.2016.09.008"},{"key":"667_CR100","doi-asserted-by":"crossref","unstructured":"Nalamachu S, Mallick-Searle T, Adler J, Chan EK, Borgersen W, Lissin DJP et al. Multimodal Therapies for the Treatment of Neuropathic Pain: The Role of Lidocaine Patches in Combination Therapy: A Narrative Review. 2025:1\u201315.","DOI":"10.1007\/s40122-025-00733-7"},{"key":"667_CR101","doi-asserted-by":"crossref","unstructured":"Ten Hoope W, Hollmann MW, de Bruin K, Verberne HJ, Verkerk AO, Tan HL et al. Pharmacodynamics and pharmacokinetics of lidocaine in a rodent model of diabetic neuropathy. 2018;128(3):609\u201319.","DOI":"10.1097\/ALN.0000000000002035"},{"key":"667_CR102","doi-asserted-by":"crossref","unstructured":"Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA. Dworkin RHJAon. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. 2004;61(6):914-8.","DOI":"10.1001\/archneur.61.6.914"},{"issue":"1","key":"667_CR103","first-page":"101","volume":"36","author":"T Buksnys","year":"2020","unstructured":"Buksnys T, Armstrong N, Worthy G, Sabatschus I, Boesl I, Buchheister B, et al. Systematic review and network meta-analysis of the efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalin. 2020;36(1):101\u201315.","journal-title":"pregabalin"},{"key":"667_CR104","doi-asserted-by":"crossref","unstructured":"Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. 2015;14(2):162\u201373.","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"667_CR105","doi-asserted-by":"crossref","unstructured":"Shoaib A, Azmi L, Pal S, Alqahtani SS, Rahamathulla M, Hani U et al. Integrating nanotechnology with naturally occurring phytochemicals in neuropathy induced by diabetes. 2022;350:118189.","DOI":"10.1016\/j.molliq.2021.118189"},{"key":"667_CR106","doi-asserted-by":"crossref","unstructured":"Ilari S, Proietti S, Russo P, Malafoglia V, Gliozzi M, Maiuolo J et al. A systematic review and meta-analysis on the role of nutraceuticals in the management of neuropathic pain in in vivo studies. 2022;11(12):2361.","DOI":"10.3390\/antiox11122361"},{"key":"667_CR107","doi-asserted-by":"crossref","unstructured":"Raafat K, Hdaib FJC. Neuroprotective effects of Moringa oleifera: Bio-guided GC-MS identification of active compounds in diabetic neuropathic pain model. 2017:1\u201310.","DOI":"10.1007\/s11655-017-2758-4"},{"key":"667_CR108","doi-asserted-by":"crossref","unstructured":"Lou J-S, Dimitrova DM, Murchison C, Arnold GC, Belding H, Seifer N et al. Centella asiatica triterpenes for diabetic neuropathy: a randomized, double-blind, placebo-controlled, pilot clinical study. 2018;20(2 Suppl 1):12.","DOI":"10.23736\/S1128-9155.18.00455-7"},{"key":"667_CR109","doi-asserted-by":"crossref","unstructured":"Kajal A, Singh, RJJoe. Coriandrum sativum improve neuronal function via inhibition of oxidative\/nitrosative stress and TNF-\u03b1 in diabetic neuropathic rats. 2020;263:112959.","DOI":"10.1016\/j.jep.2020.112959"},{"key":"667_CR110","doi-asserted-by":"crossref","unstructured":"Essmat A, Hussein MSJCTCP. Green tea extract for mild-to-moderate diabetic peripheral neuropathy A randomized controlled trial. 2021;43:101317.","DOI":"10.1016\/j.ctcp.2021.101317"},{"key":"667_CR111","doi-asserted-by":"crossref","unstructured":"Abdelkader NF, Eitah HE, Maklad YA, Gamaleldin AA, Badawi MA. Kenawy SAJLs. New combination therapy of gliclazide and quercetin for protection against STZ-induced diabetic rats. 2020;247:117458.","DOI":"10.1016\/j.lfs.2020.117458"},{"key":"667_CR112","unstructured":"Yao B, Xin Z, Wang DJJoP P. The effect of curcumin on intravitreal proinflammatory cytokines, oxidative stress markers, and vascular endothelial growth factor in an experimental model of diabetic retinopathy. 2023;74(6)."},{"issue":"9","key":"667_CR113","first-page":"10112","volume":"8","author":"M Li","year":"2015","unstructured":"Li M, Li Q, Zhao Q, Zhang J, Lin JJI. Luteolin improves the impaired nerve functions in diabetic neuropathy: behavioral and biochemical evidences. Pathol e. 2015;8(9):10112.","journal-title":"Pathol e"},{"key":"667_CR114","doi-asserted-by":"crossref","unstructured":"Wu S, Liao X, Zhu Z, Huang R, Chen M, Huang A et al. Antioxidant and anti-inflammation effects of dietary phytochemicals: The Nrf2\/NF-\u03baB signalling pathway and upstream factors of Nrf2. 2022;204:113429.","DOI":"10.1016\/j.phytochem.2022.113429"},{"issue":"27","key":"667_CR115","first-page":"2351","volume":"24","author":"L Saikia","year":"2024","unstructured":"Saikia L, Aziz Barbhuiya SA, Saikia K, Kalita P, Dutta PPJCTMC. Therapeutic Potential of Quercetin in Diabetic Neuropathy and Retinopathy. Exploring Mol Mech. 2024;24(27):2351\u201361.","journal-title":"Exploring Mol Mech"},{"key":"667_CR116","doi-asserted-by":"crossref","unstructured":"Li Z, Wang W, Meng F, Zhou Z, Zhao Z, Mei ZJJE. Analgesic and neuroprotective effects of Baimai Ointment on diabetic peripheral neuropathy. 2022;292:115122.","DOI":"10.1016\/j.jep.2022.115122"},{"key":"667_CR117","doi-asserted-by":"crossref","unstructured":"Kumar A, Shrivastava A, Suttee A, Gupta P, Shahi S, Barik R et al. Plant-Powered Nanotechnology: A Review of Green Synthesis Approaches for ZnO and Silver Nanoparticles with Medicinal Flora. 2026.","DOI":"10.2174\/0115680266413831251120132852"},{"key":"667_CR118","doi-asserted-by":"publisher","first-page":"116206","DOI":"10.1016\/j.biopha.2024.116206","volume":"171","author":"J Zheng","year":"2024","unstructured":"Zheng J, Wang R, Wang YJB. New concepts drive the development of delivery tools for sustainable treatment of diabetic complications. Pharmacotherapy. 2024;171:116206.","journal-title":"Pharmacotherapy"},{"key":"667_CR119","doi-asserted-by":"crossref","unstructured":"Khan I, Saeed K, Khan IJA. Nanoparticles: Properties, applications and toxicities. 2019;12(7):908\u2009\u2013\u200931.","DOI":"10.1016\/j.arabjc.2017.05.011"},{"key":"667_CR120","doi-asserted-by":"crossref","unstructured":"Najafi R, Hosseini A, Ghaznavi H, Mehrzadi S, Sharifi AMJBRB. Neuroprotective effect of cerium oxide nanoparticles in a rat model of experimental diabetic neuropathy. 2017;131:117\u201322.","DOI":"10.1016\/j.brainresbull.2017.03.013"},{"key":"667_CR121","doi-asserted-by":"crossref","unstructured":"Alkhalaf MI, Hussein RH, Hamza AJSJBS. Green synthesis of silver nanoparticles by Nigella sativa extract alleviates diabetic neuropathy through anti-inflammatory and antioxidant effects. 2020;27(9):2410\u20139.","DOI":"10.1016\/j.sjbs.2020.05.005"},{"key":"667_CR122","doi-asserted-by":"crossref","unstructured":"Anantaworasakul P, Chaiyana W, Michniak-Kohn BB, Rungseevijitprapa W, Ampasavate CJP. Enhanced transdermal delivery of concentrated capsaicin from chili extract-loaded lipid nanoparticles with reduced skin irritation. 2020;12(5):463.","DOI":"10.3390\/pharmaceutics12050463"},{"key":"667_CR123","doi-asserted-by":"crossref","unstructured":"Caraglia M, Luongo L, Salzano G, Zappavigna S, Marra M, Guida F et al. Stealth liposomes encapsulating zoledronic acid: a new opportunity to treat neuropathic pain. 2013;10(3):1111\u20138.","DOI":"10.1021\/mp3006215"},{"key":"667_CR124","doi-asserted-by":"crossref","unstructured":"Jia T, Rao J, Zou L, Zhao S, Yi Z, Wu B et al. Nanoparticle-encapsulated curcumin inhibits diabetic neuropathic pain involving the P2Y12 receptor in the dorsal root ganglia. 2018;11:755.","DOI":"10.3389\/fnins.2017.00755"},{"key":"667_CR125","doi-asserted-by":"crossref","unstructured":"Pebrianti S, Maulana I, Shalahuddin I, Eriyani T, Nugraha BAJD. Metabolic Syndrome, Obesity. Physical Activity to Reduce Pain Scale in Diabetic Neuropathy Patients: A Scoping Review. 2024:4079\u201389.","DOI":"10.2147\/DMSO.S483941"},{"key":"667_CR126","doi-asserted-by":"crossref","unstructured":"Khurshid S, Saeed A, Kashif M, Nasreen A, Riaz HJB. Effects of multisystem exercises on balance, postural stability, mobility, walking speed, and pain in patients with diabetic peripheral neuropathy: a randomized controlled trial. 2025;26(1):16.","DOI":"10.1186\/s12868-024-00924-6"},{"key":"667_CR127","first-page":"102","volume":"8","author":"JL Dobson","year":"2014","unstructured":"Dobson JL, McMillan J, Li LJF. Benefits Exerc intervention reducing neuropathic pain. 2014;8:102.","journal-title":"Benefits Exerc intervention reducing neuropathic pain"},{"key":"667_CR128","doi-asserted-by":"crossref","unstructured":"Zheng K, Chen C, Yang S, Wang XJF. Aerobic exercise attenuates pain sensitivity: an event-related potential study. 2021;15:735470.","DOI":"10.3389\/fnins.2021.735470"},{"key":"667_CR129","doi-asserted-by":"crossref","unstructured":"Jena D, Sahoo J, Barman A, Behera KK, Bhattacharjee S. Kumar SJJoNiRP. Type 2 diabetes mellitus, physical activity, and neuromusculoskeletal complications. 2022;13(4):705.","DOI":"10.25259\/JNRP_11_2022"},{"key":"667_CR130","doi-asserted-by":"crossref","unstructured":"Wang C, He H, Gao T, Sun X, Du L, Yang Y et al. Analgesic effect of exercise on neuropathic pain via regulating the complement component 3 of reactive astrocytes. 2024;139(4):840\u201350.","DOI":"10.1213\/ANE.0000000000006884"},{"key":"667_CR131","doi-asserted-by":"crossref","unstructured":"Vieira WF, Real CC, Martins DO, Chacur MJC. The Role of Exercise on Glial Cell Activity in Neuropathic Pain Management. 2025;14(7):487.","DOI":"10.3390\/cells14070487"},{"key":"667_CR132","doi-asserted-by":"crossref","unstructured":"Maurya SK, Gupta S, Mishra RJF. Transcriptional and epigenetic regulation of microglia in maintenance of brain homeostasis and neurodegeneration. 2023;15:1072046.","DOI":"10.3389\/fnmol.2022.1072046"},{"key":"667_CR133","doi-asserted-by":"crossref","unstructured":"Pop-Busui R, Ang L, Holmes C, Gallagher K. Feldman ELJCdr. Inflammation as a therapeutic target for diabetic neuropathies. 2016;16(3):29.","DOI":"10.1007\/s11892-016-0727-5"},{"key":"667_CR134","doi-asserted-by":"crossref","unstructured":"Ma X-Q, Qin J, Li H-Y, Yan X-L, Zhao Y, Zhang L-JJB. Role of exercise activity in alleviating neuropathic pain in diabetes via inhibition of the pro-inflammatory signal pathway. 2019;21(1):14\u201321.","DOI":"10.1177\/1099800418803175"},{"key":"667_CR135","doi-asserted-by":"crossref","unstructured":"Pepin E, Higa A, Schuster-Klein C, Bernard C, Sulpice T, Guardiola B et al. Deletion of apoptosis signal-regulating kinase 1 (ASK1) protects pancreatic beta-cells from stress-induced death but not from glucose homeostasis alterations under pro-inflammatory conditions. 2014;9(11):e112714.","DOI":"10.1371\/journal.pone.0112714"},{"key":"667_CR136","doi-asserted-by":"crossref","unstructured":"Lohmann H, Siersma V, Olivarius NFJB. Fitness consultations in routine care of patients with type 2 diabetes in general practice: an 18-month non-randomised intervention study. 2010;11(1):83.","DOI":"10.1186\/1471-2296-11-83"},{"key":"667_CR137","doi-asserted-by":"crossref","unstructured":"Sugimoto K, Yasujima M, Yagihashi SJC. Role of advanced glycation end products in diabetic neuropathy. 2008;14(10):953\u201361.","DOI":"10.2174\/138161208784139774"},{"key":"667_CR138","unstructured":"Susilaningsih FS, Komariah M, Mediawati AS, Lumbantobing VBJMJM, Sciences H. Quality of work-life among lecturers during online learning in COVID-19 pandemic period: A scoping review. 2021;17(4):163\u20136."},{"key":"667_CR139","doi-asserted-by":"crossref","unstructured":"Jensen TM, Eriksen SBM, Larsen JS, Aadahl M, Rasmussen SS, Olesen LB et al. Exercise training is associated with reduced pains from the musculoskeletal system in patients with type 2 diabetes. 2019;154:124\u20139.","DOI":"10.1016\/j.diabres.2019.07.003"},{"key":"667_CR140","doi-asserted-by":"crossref","unstructured":"Rosenberg J, Fabi A, Candido K, Knezevic N, Creamer M, Carayannopoulos A et al. Spinal cord stimulation provides pain relief with improved psychosocial function: results from EMP3OWER. 2016;17(12):2311\u201325.","DOI":"10.1093\/pm\/pnw152"},{"key":"667_CR141","doi-asserted-by":"crossref","unstructured":"Sato K, King E, Johanek L, Sluka KJE. Spinal cord stimulation reduces hypersensitivity through activation of opioid receptors in a frequency-dependent manner. 2013;17(4):551\u201361.","DOI":"10.1002\/j.1532-2149.2012.00220.x"},{"key":"667_CR142","doi-asserted-by":"crossref","unstructured":"Tsotra F, Kappel M, Peristeris P, Bader G, Levi E, Lister N et al. The societal impact of early intensified treatment in patients with type 2 diabetes mellitus. 2022;11(16):1185\u201399.","DOI":"10.2217\/cer-2022-0110"},{"key":"667_CR143","doi-asserted-by":"crossref","unstructured":"Tesfaye S, Kempler PJDR, Practice C. Conventional management and current guidelines for painful diabetic neuropathy. 2023;206:110765.","DOI":"10.1016\/j.diabres.2023.110765"},{"key":"667_CR144","doi-asserted-by":"crossref","unstructured":"Li C, Liu C-H, Li Y-F, Hu H-M, Shi Q, Liu A-X et al. 10 kHz spinal cord stimulation vs. traditional low-frequency spinal cord stimulation for the treatment of diabetes peripheral neuropathic pain: study protocol for a multi-center randomized controlled clinical trial. 2025;16:1611970.","DOI":"10.3389\/fneur.2025.1611970"},{"key":"667_CR145","doi-asserted-by":"crossref","unstructured":"Strand NH, Burkey ARJJoDS. Technology. Neuromodulation in the treatment of painful diabetic neuropathy: a review of evidence for spinal cord stimulation. 2022;16(2):332\u201340.","DOI":"10.1177\/19322968211060075"},{"key":"667_CR146","doi-asserted-by":"crossref","unstructured":"Gazzeri R, Mosca J, Occhigrossi F, Galarza M, Schiaffini R, Varrassi G et al. Spinal Cord Stimulation in Painful Diabetic Neuropathy: Advances, Outcomes, and Future Directions. 2025;13(12):3063.","DOI":"10.3390\/biomedicines13123063"},{"key":"667_CR147","doi-asserted-by":"crossref","unstructured":"Slangen R, Schaper NC, Faber CG, Joosten EA, Dirksen CD, van Dongen RT et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. 2014;37(11):3016\u201324.","DOI":"10.2337\/dc14-0684"},{"key":"667_CR148","doi-asserted-by":"crossref","unstructured":"D\u2019Souza RS, Kubrova E, Her YF, Barman RA, Smith BJ, Alvarez GM et al. Dorsal root ganglion stimulation for lower extremity neuropathic pain syndromes: an evidence-based literature review. 2022;39(10):4440\u201373.","DOI":"10.1007\/s12325-022-02244-9"},{"key":"667_CR149","doi-asserted-by":"crossref","unstructured":"Todorovic SMJIron. Painful diabetic neuropathy: prevention or suppression? 2016;127:211\u2009\u2013\u200925.","DOI":"10.1016\/bs.irn.2016.03.005"},{"key":"667_CR150","doi-asserted-by":"crossref","unstructured":"Eldabe S, Espinet A, Wahlstedt A, Kang P, Liem L, Patel NK et al. Retrospective case series on the treatment of painful diabetic peripheral neuropathy with dorsal root ganglion stimulation. 2018;21(8):787\u201392.","DOI":"10.1111\/ner.12767"},{"key":"667_CR151","doi-asserted-by":"crossref","unstructured":"Han Y-F, Cong XJFN. Comparison of the efficacy of spinal cord stimulation and dorsal root ganglion stimulation in the treatment of painful diabetic peripheral neuropathy: a prospective, cohort-controlled study. 2024;15:1366796.","DOI":"10.3389\/fneur.2024.1366796"},{"key":"667_CR152","doi-asserted-by":"crossref","unstructured":"Teh K, Wilkinson ID, Heiberg-Gibbons F, Awadh M, Kelsall A, Pallai S et al. Somatosensory network functional connectivity differentiates clinical pain phenotypes in diabetic neuropathy. 2021;64(6):1412\u201321.","DOI":"10.1007\/s00125-021-05416-4"},{"key":"667_CR153","doi-asserted-by":"crossref","unstructured":"Patel R, Kucharczyk M, Montagut-Bordas C, Lockwood S, Dickenson AHJE. Neuropathy following spinal nerve injury shares features with the irritable nociceptor phenotype: A back\u2010translational study of oxcarbazepine. 2019;23(1):183\u201397.","DOI":"10.1002\/ejp.1300"},{"key":"667_CR154","doi-asserted-by":"crossref","unstructured":"Demartini L, Bonezzi CJEN. Neuropathic pain: proposal of a mechanism-based treatment. 2025;4:100686.","DOI":"10.37349\/en.2025.100686"},{"key":"667_CR155","doi-asserted-by":"crossref","unstructured":"Selvarajah D, Sloan G, Teh K, Wilkinson ID, Heiberg-Gibbons F, Awadh M et al. Structural brain alterations in key somatosensory and nociceptive regions in diabetic peripheral neuropathy. 2023;46(4):777\u201385.","DOI":"10.2337\/dc22-1123"},{"key":"667_CR156","doi-asserted-by":"crossref","unstructured":"Raputova J, Rajdova A, Vollert J, Srotova I, Rebhorn C, \u00dc\u00e7eyler N et al. Continuum of sensory profiles in diabetes mellitus patients with and without neuropathy and pain. 2022;26(10):2198\u2013212.","DOI":"10.1002\/ejp.2034"},{"issue":"4","key":"667_CR157","first-page":"542","volume":"49","author":"J-E Lee","year":"2025","unstructured":"Lee J-E, Won JCJD. Clinical phenotypes of diabetic peripheral neuropathy: implications for phenotypic-based therapeutics strategies. J M. 2025;49(4):542\u201364.","journal-title":"J M"},{"key":"667_CR158","doi-asserted-by":"crossref","unstructured":"Themistocleous AC, Crombez G, Baskozos G, Bennett DLJP. Using stratified medicine to understand, diagnose, and treat neuropathic pain. 2018;159:S31\u201342.","DOI":"10.1097\/j.pain.0000000000001301"},{"key":"667_CR159","doi-asserted-by":"crossref","unstructured":"Bhagar R, Le-Niculescu H, Corey S, Gettelfinger A, Schmitz M, Ebushi A et al. Next-generation precision medicine for pain. 2025:1\u201326.","DOI":"10.1038\/s41398-024-03071-y"},{"issue":"2","key":"667_CR160","first-page":"204","volume":"24","author":"RR Edwards","year":"2023","unstructured":"Edwards RR, Schreiber KL, Dworkin RH, Turk DC, Baron R, Freeman R, et al. Optimizing and accelerating the development of precision pain treatments for chronic pain. IMMPACT Rev recommendations. 2023;24(2):204\u201325.","journal-title":"IMMPACT Rev recommendations"},{"key":"667_CR161","doi-asserted-by":"crossref","unstructured":"Raputova J, Srotova I, Vlckova E, Sommer C, \u00dc\u00e7eyler N, Birklein F et al. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. 2017;158(12):2340\u201353.","DOI":"10.1097\/j.pain.0000000000001034"},{"issue":"1","key":"667_CR162","first-page":"41","volume":"5","author":"EL Feldman","year":"2019","unstructured":"Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabet neuropathy. 2019;5(1):41.","journal-title":"Diabet neuropathy"},{"issue":"1","key":"667_CR163","first-page":"24","volume":"54","author":"T-M Ko","year":"2016","unstructured":"Ko T-M, Wong C-S, Wu J-Y, Chen Y-TJAAT. Pharmacogenomics personalized pain Med. 2016;54(1):24\u201330.","journal-title":"Pharmacogenomics personalized pain Med"},{"key":"667_CR164","doi-asserted-by":"crossref","unstructured":"Pollastro C, Ziviello C, Costa V, Ciccodicola AJP. therapies? Pharmacogenomics of drug response in type 2 diabetes: toward the definition of tailored 2015;2015(1):415149.","DOI":"10.1155\/2015\/415149"},{"key":"667_CR165","doi-asserted-by":"crossref","unstructured":"Cregg R, Russo G, Gubbay A, Branford R, Sato, HJBjop. Pharmacogenetics analgesic drugs. 2013;7(4):189\u2013208.","DOI":"10.1177\/2049463713507439"},{"key":"667_CR166","doi-asserted-by":"crossref","unstructured":"Kringel D, L\u00f6tsch JJP. Knowledge of the genetics of human pain gained over the last decade from next-generation sequencing. 2025;214:107667.","DOI":"10.1016\/j.phrs.2025.107667"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00667-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00667-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00667-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:37:39Z","timestamp":1790645859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00667-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":166,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["667"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00667-1","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used AI-assisted tools (Grammarly and Mendeley) for language editing and literature management. All scientific content and conclusions were independently developed and verified by the authors.","order":2,"name":"Ethics","label":"AI use disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"84"}}